businesspress24.com - Simavita Limited: Results of Special Meeting
 

Simavita Limited: Results of Special Meeting

ID: 1417779

(firmenpresse) - SYDNEY, AUSTRALIA -- (Marketwired) -- 02/25/16 -- Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company") is pleased to announce the results of the Special Meeting of the Company''s shareholders which was held at 10:00 am today (Australian Eastern Daylight Time) in North Sydney, Australia.

All three resolutions that were put before the meeting were passed unanimously on a show of hands. Details of the proxy votes received by the Company in relation to each resolution in the notice of special meeting and information circular are contained in the following table.

About Simavita

Simavita is a digital healthcare company that has developed an innovative software platform. The first application for the platform is a world first solution for the management of urinary incontinence, with a focus on the elderly. This platform technology is an instrumented incontinence assessment application that provides evidence-based incontinence management care plans to the residential aged care market.

About SIM®

SIM® is a wireless sensor technology that delivers evidence-based instrument incontinence data on individuals. SIM® provides user friendly tools and software to assess the incontinence condition and to help plan better outcomes. SIM® is used to detect, record and report incontinence events during a compulsory or recommended assessment period in residential aged care facilities to develop an evidence-based incontinence care plan.

Conducting assessments is mandatory in many countries and the incontinence assessment creates an influential element of care of each individual. For more information on Simavita or SIM®, please visit .

The TSX Venture Exchange has in no way passed upon the merits of the transactions set out herein and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange not its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this Release.







Contacts:
Company
Philippa Lewis
Chief Executive Officer
+61 2 8405 6381

Media and Investor Relations
Glen Zurcher
+61 420 249 299

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Cystic Fibrosis Therapeutics in Major Developed Market Worth $4.0 Billion by 2019: Radiant Insights, Inc.
Versandapotheke-potenzmittel.com Now Ensures Quick and Safe Delivery of Medications
Bereitgestellt von Benutzer: Marketwired
Datum: 25.02.2016 - 09:21 Uhr
Sprache: Deutsch
News-ID 1417779
Anzahl Zeichen: 286

contact information:
Contact person:
Town:

SYDNEY, AUSTRALIA


Phone:

Kategorie:

Alternative


Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:


Diese Pressemitteilung wurde bisher 152 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Simavita Limited: Results of Special Meeting
"
steht unter der journalistisch-redaktionellen Verantwortung von

Simavita Limited (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Simavita Limited



 

Who is online

All members: 10 565
Register today: 0
Register yesterday: 2
Members online: 0
Guests online: 41


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.